Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Fundamental data now powered by FactSet with hourly updates!

CFRX | ContraFect Corp

Index	-	P/E	-	EPS (ttm)	-53.49	Insider Own	0.10%	Shs Outstand	10.70M	Perf Week	-6.19%
Market Cap	5.67M	Forward P/E	-	EPS next Y	-1.95	Insider Trans	0.00%	Shs Float	10.69M	Perf Month	-26.19%
Income	-35.84M	PEG	-	EPS next Q	-0.72	Inst Own	1.14%	Short Float / Ratio	0.13% / 0.24	Perf Quarter	-64.31%
Sales	0.00M	P/S	-	EPS this Y	96.93%	Inst Trans	-85.35%	Short Interest	0.01M	Perf Half Y	-77.25%
Book/sh	-0.10	P/B	-	EPS next Y	48.68%	ROA	-119.38%	Target Price	5.00	Perf Year	-96.26%
Cash/sh	1.35	P/C	0.39	EPS next 5Y	12.70%	ROE	-608.73%	52W Range	0.51 - 15.76	Perf YTD	-93.10%
Dividend	-	P/FCF	-	EPS past 5Y	11.02%	ROI	-4073.30%	52W High	-96.64%	Beta	0.52
Dividend %	-	Quick Ratio	1.00	Sales past 5Y	0.00%	Gross Margin	-	52W Low	3.92%	ATR	0.09
Employees	23	Current Ratio	1.00	Sales Q/Q	-	Oper. Margin	0.00%	RSI (14)	26.02	Volatility	11.91% 14.32%
Optionable	No	Debt/Eq	-	EPS Q/Q	94.73%	Profit Margin	-	Rel Volume	0.72	Prev Close	0.58
Shortable	Yes	LT Debt/Eq	-	Earnings	Aug 14 BMO	Payout	-	Avg Volume	59.69K	Price	0.53
Recom	1.00	SMA20	-19.79%	SMA50	-39.86%	SMA200	-81.79%	Volume	43,126	Change	-8.62%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-14-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$1
Jul-14-22	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$15 → $1
Feb-02-22	Upgrade	WBB Securities	Speculative Buy → Buy	$6.50
Sep-09-21	Initiated	SVB Leerink	Outperform	$14
Jun-09-20	Initiated	Mizuho	Buy	$12
Jun-09-20	Initiated	Cantor Fitzgerald	Overweight	$15
Jul-28-16	Initiated	Piper Jaffray	Overweight
Jul-22-16	Downgrade	Maxim Group	Buy → Hold
Mar-15-16	Reiterated	Maxim Group	Buy	$8 → $7
Dec-31-15	Reiterated	Maxim Group	Buy	$16 → $9

Sep-21-23 09:40AM	CFRX: IND Application for CF-370 Submitted to FDA (Zacks Small Cap Research) +5.29%
Sep-19-23 08:30AM	ContraFect to Present at the ASM/ESCMID Joint Conference on Drug Development (GlobeNewswire)
Sep-18-23 07:30AM	ContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370 (GlobeNewswire)
Aug-28-23 08:00AM	ContraFect to Present at the World Anti-Microbial Resistance Congress 2023 (GlobeNewswire)
Aug-17-23 09:41AM	CFRX: CF-370 IND to be Filed in 3Q23 (Zacks Small Cap Research)
08:38AM	Loading…
Aug-14-23 08:38AM	ContraFect: Q2 Earnings Snapshot (AP Finance)
08:30AM	ContraFect Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Jun-27-23 08:30AM	ContraFect Enters Into a Warrant Exercise Transaction for Proceeds of $9.6 Million (GlobeNewswire) +7.41%
Jun-22-23 07:06AM	CFRX: CF-370 Effective in Rabbit Lung Infection Model Caused by Klebsiella Pneumoniae (Zacks Small Cap Research)
Jun-20-23 08:59AM	ContraFect Data Presentations at ASM Microbe 2023 Demonstrate the Power of the Companys Proprietary Platform to Discover New Agents Targeting Antibiotic-Resistant Gram-negative Pathogens (GlobeNewswire)
Jun-08-23 04:01PM	ContraFect to Present New Data Demonstrating the Potential Efficacy of Its Engineered Lysins Against Antibiotic-Resistant Pathogens at ASM Microbe 2023 (GlobeNewswire)
May-23-23 06:31AM	CFRX: First Patient Dosed in Phase 1b/2 Trial of Exebacase for the Treatment of Chronic Prosthetic Joint Infections (Zacks Small Cap Research)
May-15-23 08:16AM	ContraFect: Q1 Earnings Snapshot (AP Finance) +12.00%
08:00AM	ContraFect Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Apr-27-23 04:24PM	What's Going On With ContraFecta Stock Today (Benzinga) +46.97%
09:00AM	Loading…
Apr-26-23 09:00AM	ContraFect Announces First Patient Dosed in the Phase 1b/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee (GlobeNewswire) -15.38%
Apr-20-23 08:30AM	ContraFect Data Presentations at the 33rd Annual ECCMID Meeting Highlight the Potential Efficacy of Lysin CF-370 Against Antibiotic Resistant Gram-negative Pathogens (GlobeNewswire) +13.07%
Apr-13-23 06:26AM	CFRX: Initiates Phase 1 Trial for Exebacase in Chronic Prosthetic Joint Infection (Zacks Small Cap Research) -7.08%
Apr-06-23 08:30AM	ContraFect Announces Multiple Presentations of New Data at the 33rd Annual ECCMID Meeting (GlobeNewswire)
Apr-03-23 08:30AM	ContraFect Announces Initiation of a Phase 1b/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee (GlobeNewswire) -13.39%
Mar-31-23 08:30AM	ContraFect Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire) -16.44%
Feb-28-23 08:30AM	ContraFect Announces Pricing of $10.0 Million Registered Direct Offering and Concurrent Private Placement (GlobeNewswire) -26.79%
Dec-20-22 09:35AM	ContraFect Announces Lopsided Interim Results From Pivotal Bacterial Infection Study (Benzinga)
Dec-19-22 04:30PM	ContraFect Provides Update from the Futility Analysis of the Phase 3 DISRUPT Study of Exebacase (GlobeNewswire)
Dec-13-22 08:01AM	ContraFect Announces Pricing of $7.0 Million Registered Direct Offering and Concurrent Private Placement (GlobeNewswire) -20.31%
Nov-30-22 08:34AM	CFRX: Cleared to Begin Clinical Trial for Exebacase in Chronic Prosthetic Joint Infection (Zacks Small Cap Research) +16.95%
Nov-28-22 08:00AM	ContraFect Announces ANSM Approval of Clinical Trial Application for Exebacase in Prosthetic Joint Infections (GlobeNewswire)
Nov-22-22 05:21AM	CFRX: Exebacase to be Evaluated as Treatment for Prosthetic Joint Infections (Zacks Small Cap Research) +11.19%
Nov-14-22 08:00AM	ContraFect Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Sep-12-22 07:32AM	ContraFect Announces Multiple Publications Highlighting the Potential Utility of Lysins for the Treatment of Bone and Joint Infections (GlobeNewswire)
07:30AM	Loading…
07:30AM	ContraFect Announces Presentation of New Clinical Data From a Study Using Exebacase in the LysinDAIR Procedure on Patients With Chronic Knee Prosthetic Joint Infection (GlobeNewswire)
Sep-01-22 07:15AM	CFRX: Exebacase Shows Potent Antimicrobial Activity in Implant-Associated MRSA Osteomyelitis (Zacks Small Cap Research) -7.74%
Aug-15-22 01:08PM	ContraFect Cuts Workforce After Trial Setback (Benzinga)
08:30AM	ContraFect Reports Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
08:25AM	ContraFect Announces Publication on Exebacase and CF-296 Demonstrating Potent In Vivo Antimicrobial Activity in Implant-Associated MRSA Osteomyelitis (GlobeNewswire)
Jul-14-22 10:05AM	CFRX: DSMB Recommends DISRUPT Study be Stopped for Futility (Zacks Small Cap Research) -83.11%
Jul-13-22 04:05PM	ContraFect Announces Independent DSMB Recommends Exebacase Phase 3 DISRUPT Study Be Stopped for Futility Following Interim Analysis (GlobeNewswire)
Jun-27-22 12:02PM	We're Not Very Worried About ContraFect's (NASDAQ:CFRX) Cash Burn Rate (Simply Wall St.) -6.19%
Jun-14-22 07:30AM	Presentations at ASM Microbe Conference Demonstrate Potential of ContraFects Direct Lytic Agents (DLAs) to Address MRSA Infections (GlobeNewswire) -5.47%
Jun-06-22 07:30AM	ContraFect to Present Data Demonstrating the Potential of Its Direct Lytic Agents (DLAs) to Combat MRSA at ASM Microbe 2022 (GlobeNewswire)
May-26-22 07:20AM	CFRX: Results from Interim Futility Analysis in July 2022 (Zacks Small Cap Research)
May-23-22 08:00AM	Enlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman (GlobeNewswire)
May-20-22 08:30AM	ContraFect Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-16-22 07:30AM	ContraFect Reports First Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Apr-27-22 09:00AM	Keynotes, Educational Panels and 88 Companies to Present at the Planet MicroCap Showcase on May 3-5, 2022 at Bally's Hotel & Casino in Las Vegas, NV (ACCESSWIRE)
08:00AM	ContraFect Data Presentations at the 32nd Annual ECCMID Meeting Highlight the Potential of Engineered Lysin CF-370 to Improve Clinical Outcomes and Suppress Antimicrobial Resistance Compared to Antibiotics Alone (GlobeNewswire)
Apr-18-22 07:30AM	ContraFect Announces Multiple Presentations of New Data Demonstrating the Potential of Its Direct Lytic Agents (DLAs) to Address Antimicrobial Resistance at the 32nd Annual ECCMID Meeting (GlobeNewswire) +10.31%
Apr-04-22 07:15AM	CFRX: Futility Analysis for DISRUPT Trial in 1H22 (Zacks Small Cap Research) +6.56%
Mar-24-22 08:00AM	ContraFect Reports Fourth Quarter 2021 and Full Year 2021 Financial Results and Provides Business Update (GlobeNewswire)
Mar-21-22 08:30AM	ContraFect to Present at the Maxim Group 2022 Virtual Growth Conference (GlobeNewswire)
Mar-02-22 04:20AM	ContraFect Corporation (NASDAQ:CFRX): When Will It Breakeven? (Simply Wall St.)
Feb-10-22 07:30AM	ContraFect to Present at the SVB Leerink 11th Annual Global Healthcare Conference (GlobeNewswire)
Jan-06-22 04:05PM	ContraFect Announces Award from the Cystic Fibrosis Foundation to Evaluate Exebacase as a Potential Treatment for Serious MRSA Lung Infections Associated with Cystic Fibrosis (GlobeNewswire)
Jan-01-22 07:23AM	How Much Of ContraFect Corporation (NASDAQ:CFRX) Do Institutions Own? (Simply Wall St.)
Dec-20-21 09:00AM	Compassionate Use Case Study Demonstrating the Potential of Investigational Direct Lytic Agent Exebacase to Treat MRSA Bacteremia in Pediatric Populations Published in Clinical Infectious Diseases (GlobeNewswire)
Nov-30-21 05:52AM	CFRX: Direct Lytic Agents Show In Vitro Activity Against Gram-Negative Pathogens (Zacks Small Cap Research) +5.90%
Nov-15-21 07:30AM	ContraFect Reports Third Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire) -8.94%
Nov-09-21 07:30AM	ContraFects New Data Presented at NACFC Demonstrate Potential of Direct Lytic Agents to Treat Pulmonary Infections in Patients with Cystic Fibrosis (GlobeNewswire)
Nov-01-21 07:11AM	We Think ContraFect (NASDAQ:CFRX) Needs To Drive Business Growth Carefully (Simply Wall St.)
Oct-26-21 07:30AM	ContraFect to Present Data on the Potential of DLAs to Treat Pulmonary Infections in Cystic Fibrosis Patients (GlobeNewswire)
Oct-12-21 06:26AM	CFRX: New Data on Exebacase Shows Rapid Resolution of Symptoms in Phase 2 Trial (Zacks Small Cap Research)
Oct-04-21 09:00AM	ContraFects New Phase 2 Exebacase Data Presented at IDWeekTM Demonstrates Rapid Symptom Resolution Among Patients with Staphylococcus aureus Bacteremia (GlobeNewswire)
Sep-29-21 07:30AM	ContraFect to Present New Late Breaking Phase 2 Exebacase Data on Rapid Symptom Resolution Among Patients with Staphylococcus aureus Bacteremia at IDWeek 2021 (GlobeNewswire)
Sep-22-21 07:30AM	ContraFect Corporation to Present at the 2021 Cantor Global Virtual Healthcare Conference (GlobeNewswire)
Aug-30-21 07:18AM	CFRX: Awaiting Interim Futility Analysis for Phase 3 DISRUPT Trial (Zacks Small Cap Research)
Aug-13-21 07:30AM	ContraFect Reports Second Quarter 2021 Financial Results and Provides Business Update (GlobeNewswire)
Jul-27-21 10:27PM	Were Hedge Funds Right About ContraFect Corp (CFRX)? (Insider Monkey)
Jul-26-21 05:53AM	CFRX: Presentations at ECCMID Highlight Advances in Lysin Platform (Zacks Small Cap Research)
Jul-19-21 07:31AM	ContraFect Announces Multiple Presentations of New Research Data From Its Pipeline of Direct Lytic Agents at the 31st ECCMID (GlobeNewswire)
07:30AM	ContraFect Announces Multiple Publications on CF-296 Demonstrating Potent In Vivo Antimicrobial Activity (GlobeNewswire)
Jun-28-21 02:54AM	What You Need To Know About ContraFect Corporation's (NASDAQ:CFRX) Investor Composition (Simply Wall St.)
Jun-24-21 10:42AM	2 Strong Buy Penny Stocks With Massive Upside Potential (TipRanks) +7.63%
Jun-17-21 07:31AM	ContraFect Appoints Gary Woodnutt, Ph.D. as Senior Vice President of Translational Sciences and Preclinical Development (GlobeNewswire)
07:30AM	ContraFect Invited to Present New Research Data From Its Pipeline of Direct Lytic Agents at World Microbe Forum (GlobeNewswire)
May-26-21 07:30AM	ContraFect Announces Multiple Publications on Exebacase, Including First Manuscript on Local Administration of Lysin for Potential Treatment of Prosthetic Joint Infections (GlobeNewswire)
May-24-21 08:19AM	CFRX: Interim Futility Analysis for Phase 3 DISRUPT Trial in 2H21 (Zacks Small Cap Research)
May-14-21 07:30AM	ContraFect Reports First Quarter 2021 Financial Results and Provides Business Update (GlobeNewswire) +6.98%
May-03-21 07:30AM	ContraFect Announces Issuance of Composition of Matter Patent for CF-370 by the United States Patent and Trademark Office (GlobeNewswire) -7.67%
Apr-26-21 07:30AM	ContraFect Invited to Participate in the Cystic Fibrosis Target Product Profile Virtual Symposium (GlobeNewswire)
Apr-15-21 06:30PM	ContraFect Invited to Present at the Inaugural Anti-Infectives Drug Development Summit (GlobeNewswire)
Apr-09-21 06:40AM	CFRX: Raises $53.7 Million in Public Offering (Zacks Small Cap Research)
Mar-30-21 07:30AM	ContraFect Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update (GlobeNewswire)
03:00AM	Is ContraFect (NASDAQ:CFRX) In A Good Position To Invest In Growth? (Simply Wall St.)
Mar-22-21 04:05PM	ContraFect Corporation Announces Closing of Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire)
Mar-17-21 04:01PM	ContraFect Corporation Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Mar-16-21 06:27AM	CFRX: $86.8 Million BARDA Contract to Support Phase 3 Trial of Exebacase (Zacks Small Cap Research)
Mar-12-21 07:36AM	The Daily Biotech Pulse: Novavax Vaccine Data, ContraFect Secures BARDA Funding, 2 IPOs (Benzinga)
Mar-11-21 04:05PM	ContraFect Announces BARDA Contract Award for Up to $86.8 Million and Provides Business Outlook (GlobeNewswire) +25.00%
Feb-11-21 07:00AM	ContraFect Announces Appointment of Dr. Jane F. Barlow to Board of Directors (GlobeNewswire)
Dec-30-20 12:55AM	What Kind Of Shareholders Hold The Majority In ContraFect Corporation's (NASDAQ:CFRX) Shares? (Simply Wall St.)
Dec-11-20 05:59PM	Is CFRX A Good Stock To Buy Now? (Insider Monkey)
Nov-24-20 06:56AM	CFRX: Enrollment Continues in Phase 3 Trial of Exebacase (Zacks Small Cap Research) +12.30%
Nov-13-20 08:33AM	ContraFect Reports Third Quarter 2020 Financial Results and Provides Business Update (GlobeNewswire) +5.88%
Oct-31-20 08:00AM	Kaskela Law LLC Announces Stockholder Investigation of ContraFect Corporation - CFRX (ACCESSWIRE)
Oct-26-20 07:00AM	ContraFect Initiates Expanded Access to Exebacase for the Treatment of MRSA Bloodstream Infections in COVID-19 Patients (GlobeNewswire)
Oct-01-20 07:31AM	We're Keeping An Eye On ContraFect's (NASDAQ:CFRX) Cash Burn Rate (Simply Wall St.)
Sep-09-20 07:30AM	ContraFect to Present at the 2020 Cantor Global Virtual Healthcare Conference (GlobeNewswire) +8.51%
Aug-25-20 07:30AM	ContraFect Announces Funding Agreement with the Cystic Fibrosis Foundation (GlobeNewswire)
Aug-19-20 05:50AM	CFRX: Enrollment Continues in Phase 3 Trial of Exebacase (Zacks Small Cap Research) -6.53%
Aug-14-20 07:30AM	ContraFect Reports Second Quarter 2020 Financial Results and Provides Business Update (GlobeNewswire)

ContraFect Corp. is a clinical stage biotechnology company, which engages in the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its product pipeline consists of CF-301, Gram-Negative Lysins, and Amurin Peptides. The company was founded by Robert Nowinski on March 5, 2008 and is headquartered in Yonkers, NY.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CFRX | ContraFect Corp

Upgrade your FINVIZ experience